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Th  e work of Gardner and colleagues [1] focuses the 
attention of breast cancer research on the small (23 to 
25 kDa) protein Geminin, which is unique to multicellular 
animals. Geminin plays a pivotal role in coordinating 
DNA replication and cell division [2], as well as a role in 
specifying cell fate [3,4]. It accomplishes these varied 
tasks by inhibiting the activity of proteins involved in 
regulating genome duplication and gene expression [3,5-
7]. Th   e most well characterized example is Cdt1, one of 
eight proteins essential for loading the replicative DNA 
helicase (Mcm(2-7)) onto DNA replication origins. 
Geminin inhibition of Cdt1, however, is only one of ﬁ  ve 
concerted pathways in metazoan cells that restrict 
nuclear DNA replication to one complete round per cell 
division, thereby maintaining genome stability and pre-
vent  ing cells from becoming aneuploid. However, since 
Geminin is selectively expressed in proliferating cells, 
and its level in cancer cells is markedly greater than in 
normal cells, it can be used as a biomarker for both the 
diagnosis and prognosis of cancer [8]. Moreover, 
suppression of Geminin has been suggested as a novel 
strategy for killing cancer cells with little or no eﬀ  ect on 
normal cells [9]. In contrast to normal cells, many cancer 
cells rely exclusively on Geminin to prevent reinitiation 
of DNA replication before mitosis is completed. Deple-
tion of Geminin in these cells induces DNA re-replica-
tion, which results in accumulation of stalled replication 
forks and DNA damage. Th   is, in turn, triggers apoptosis.
Working with human mammary epithelial (HME) cells, 
Gardner and colleagues [1] discovered that Geminin 
facilitates the ability of Topoisomerase IIα (TopoIIα) to 
bind chromatin and resolve catenated intertwines, and 
that this trimolecular interaction appears to be regulated 
by two protein kinases, one (CKIε) that activates TopoIIα, 
and one (Cdc7-Dbf4) that inhibits TopoIIα. Without 
TopoIIα activity, sister chromatids accumulate catenated 
intertwines during S-phase that prevent their separation 
during mitosis. Th   is, in turn, triggers the spindle 
assembly checkpoint to arrest cells at metaphase and 
then induce apoptosis. Indeed, several chemo  thera  peutic 
drugs promote this reaction by inhibiting TopoIIα. HME 
cells treated with siRNA against Geminin also rapidly 
accumulate with 4N DNA content (G2 or M phase) and 
fail to complete cytokinesis due to chromo  some bridges 
that remain between the two nuclei. Th  is means that 
TopoIIα activity is suppressed during G1 phase when 
Geminin is absent and Cdc7-Dbf4 is present, but TopoIIα 
activity is facilitated from S through meta  phase when 
Geminin is present. Th   us, Geminin not only suppresses 
initiation of DNA replication, but also promotes 
termination of DNA replication forks.
Th  ere is, however, a signiﬁ  cant  diﬀ  erence  between 
inhibiting TopoIIα binding to chromatin by suppressing 
Geminin and chemical inhibition of TopoIIα activity. 
Chemical inhibitors arrest cells in G2/M phase, but these 
cells soon by-pass the spindle assembly checkpoint and 
attempt to replicate their genome, a phenomenon termed 
‘mitotic slippage’ [10]. Mitotic slippage occurs most 
frequently in cancer cells that lack p53 and Rb, 
components of checkpoints that prevent premature 
entrance into S phase. In contrast, siRNA depletion of 
Geminin in synchronized HME cells also suppressed 
expression of cyclins E and A1, Cdk1 and Cdk2, which 
would prevent initiation of DNA replication [11]. 
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© 2011 BioMed Central LtdHowever, this was not observed when Geminin was 
depleted in ten other cell lines derived from normal 
human tissues and three from cancer tissues [9]. Th  ese 
cells continued to proliferate normally and re-replicated 
their DNA only when both Geminin and cyclin A1 were 
suppressed. Cdk2-cyclin A1 is required in three of the 
ﬁ  ve pathways that prevent DNA re-replication. In vivo, 
Geminin is largely dispensable for embryonic and adult 
mammalian neurogenesis [12], and it is not required for 
self-renewal of hematopoietic stem cells or baseline 
production of granulocytes or monocytes [13]. Th  us, 
Geminin depletion is a promising therapy for killing 
cancer cells without interfering with normal cell 
proliferation.
Remarkably, over-expression of Geminin in HME cells 
triggers DNA re-replication (production of cells with 
>4N DNA). Under these conditions, TopoIIα cleaves the 
DNA without resealing the duplex and then dissociates 
from chromatin, leaving behind damaged DNA. However, 
since Geminin over-expression in HME cells is accom  pa-
nied by suppression of both CHK1 and H2AX (compo-
nents of the DNA damage response mechanism), and up-
regulation of cyclin A1 and Cdk1 expression, this allows 
these cells to re-replicate their DNA and become 
aneuploid. Since TopoIIα is not associated with chroma  tin 
under these conditions, cells that over-express Geminin 
will be less sensitive to TopoIIα inhibitors that rely on 
trapping the TopoIIα-DNA adduct at the site of TopoIIα 
cleavage. Th  us, the natural tendency of cancer cells to 
over-express Geminin may facilitate their ability to 
undergo chromosomal rearrangements and to resist the 
eﬀ  ects of TopoIIα inhibitors. Perhaps the high percentage 
of patients who do not respond to chemotherapeutic 
inhibitors of TopoIIα would respond if TopoIIα inhibitors 
were combined with anti-Geminin agents.
Th  e  eﬀ  ects of altering Geminin levels appear to depend 
on the cell and its genotype. Geminin depletion induces 
DNA re-replication in most, but not all, cancer cells [1,9]. 
Conversely, Geminin depletion does not arrest prolifera-
tion of non-cancer cells in vitro [9], nor does ablation of 
the Geminin gene prevent proliferation of all cell types in 
vivo [12,13]. However, some non-cancer breast cells may 
arrest in mitosis without inducing DNA re-replication or 
apoptosis [11]. Over-expression of a nondegradable form 
of Geminin in primary human ﬁ  broblasts arrests them in 
G1 without apoptosis, whereas over-expression in osteo-
sarcoma cells induces apoptosis [14]. Th  e fact that 
osteosarcoma cells expressing both p53 and Rb arrest in 
early S phase, whereas osteosarcoma cells that lack these 
genes accumulate in late S and G2/M, suggests that 
normal cells contain an ‘origin licensing checkpoint’ that 
prevents premature entrance into S phase [15], a 
hypothesis also supported by suppression of origin 
licensing proteins [16]. Cancer cells that lack this 
checkpoint would be vulnerable to drugs that increase 
Geminin activity. Th  us, the ability to selectively kill 
cancer cells by either depletion or over-expression of 
Geminin bodes well for Geminin-based chemotherapies, 
but it remains to be determined through live animal 
studies just how useful such therapies will be.
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